| 前收盘价格 | 2.52 |
| 成交量 | 220,469 |
| 预期市盈率 (P/E Forward) | 1.23 |
| 价格/销量 (P/S) | 1.18 |
| 股市价格/股市净资产 (P/B) | 0.510 |
| 52周波幅 |
| 营业毛利率 | -71.24% |
| 营业利益率 (TTM) | -169.85% |
| 稀释每股收益 (EPS TTM) | -2.13 |
| 季度收入增长率 (YOY) | 0.80% |
| 总债务/股东权益 (D/E MRQ) | 228.52% |
| 流动比率 (MRQ) | 1.72 |
| 营业现金流 (OCF TTM) | -74.37 M |
| 杠杆自由现金流 (LFCF TTM) | -50.02 M |
| 资产报酬率 (ROA TTM) | -32.37% |
| 股东权益报酬率 (ROE TTM) | -746.25% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Fortress Biotech, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-0.6
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.64 |
|
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 21.11% |
| 机构持股比例 | 16.39% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Opaleye Management Inc. | 30 Jun 2026 | 890,000 |
| Mackenzie Financial Corp | 30 Jun 2026 | 555,676 |
| Gsa Capital Partners Llp | 30 Jun 2026 | 458,472 |
| Shikiar Asset Management Inc | 30 Jun 2026 | 305,469 |
| Bridgeway Capital Management, Llc | 30 Jun 2026 | 177,368 |
| Hb Wealth Management, Llc | 30 Jun 2026 | 116,675 |
| Kestra Advisory Services, Llc | 30 Jun 2026 | 116,235 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合